We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for mirvetuximab soravtansine (Abbvie Pty Ltd)
Active ingredients
mirvetuximab soravtansine
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Concentrate solution for intravenous infusion
Indication
For the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer
Therapeutic area
Oncology